SIGNIFICANT AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The following table summarizes our total consolidated net revenues from collaborators, for the periods indicated, in thousands:

	Year Ended December 31,
Description	2017		2016		2015
Sanofi Genzyme	$	54,625	$	32,015	$	11,005
MDCO		30,217		11,220		10,301
Takeda		—		—		8,867
Monsanto		2,500		—		5,621
Other		2,570		3,924		5,303
Total net revenues from collaborators	$	89,912	$	47,159	$	41,097

Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Each Significant Agreement

The following table provides the research and development expenses incurred by type that are directly attributable to each significant agreement for the periods indicated, in thousands:

	Year Ended December 31,
	2017						2016						2015
	Sanofi Genzyme		MDCO		Ionis		Sanofi Genzyme		MDCO		Ionis		Sanofi Genzyme		MDCO		Ionis
Research and development
Clinical trial and manufacturing	$	174,901	$	5,421	$	—	$	150,179	$	1,211	$	—	$	108,903	$	3,308	$	—
External services		4,475		—		3,250		7,366		—		—		3,151		770		—
Other		5,327		106		—		3,035		64		525		3,714		497		3,300
Total research and development expenses	$	184,703	$	5,527	$	3,250	$	160,580	$	1,275	$	525	$	115,768	$	4,575	$	3,300

The following table presents information related to the 2014 Sanofi Genzyme collaboration, in thousands:

Excess of fair value of our common stock issued to Sanofi Genzyme in February 2014	$	(51,450	)
Deferred revenue remaining under the 2012 Sanofi Genzyme agreement upon execution of the 2014 Sanofi Genzyme collaboration		33,500
Milestone payment received:
Year-ended December 31, 2014		25,000
Development expense reimbursement from Sanofi Genzyme:
Year-ended December 31, 2015		33,949
Year-ended December 31, 2016		54,337
Year-ended December 31, 2017		51,846
Total consideration at December 31, 2017	$	147,182
Cumulative revenue recognized at December 31, 2017	$	98,014
Deferred revenue at December 31, 2017	$	49,168